Compare peptides
Put two entries side by side — evidence, mechanism, risks, and community claims.
Adamax
Anecdotal
Research chemical
Summary
Designer Semax analog featuring terminal modifications (acetylation ± adamantane-related) intended to improve stability and BBB penetration; almost no independent peer-reviewed identity.
Categories
Cognitive & Nootropic
Mechanism
Presumed Semax-like melanocortin/BDNF-pathway activity with chemical modifications aimed at longer half-life and better CNS delivery. Parent Semax has Russian clinical literature; Adamax does not.
Half-life
Unknown (designed longer than Semax; unpublished PK)
Routes
Intranasal; Subcutaneous injection
Legal / access
No independent clinical approval. Designer research peptide; verify COA identity.
Key risks
- Nasal irritation
- Head pressure
- Insomnia if late dosing
- Unknown unique risks
Common claims
- Stronger/longer Semax
- Focus and neuroprotection
- Nasal nootropic
Select peptide B